Research programme: STMN2 splicing modulators - Alcatraz Therapeutics
Latest Information Update: 25 Mar 2025
At a glance
- Originator Alcatraz Therapeutics
- Class Small molecules
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders